The invention is situated in the field of cancer treatment. In particular it relates to treatments comprising combining an inhibitor of the pyrimidinergic receptor P2Y6 and an immune checkpoint inhibitor. Further in particular, the treatment is of benefit for cancers poorly responding to immune checkpoint inhibitor therapy.

Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a polyethylene glycol (PEG) receptors and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

Compounds, compositions and methods for reducing off-target toxicity of T cells expressing a chimeric antigen receptor (CAR-T cells) and/or providing enhanced control of CAR-T cell activation, and methods of treating a subject and/or modifying CAR-T cell activity in a subject with cancer.

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

Chimeric antigen receptor (CAR) T-cell-rejuvenating conjugates and compositions and methods of use to rejuvenate exhausted CAR T-cells.

The present invention provides a method of creating a chemically-induced heterodimerizing system having three different components that form a ternary complex by amendment of a chemically induced homodimerizing system, wherein said chemically induced homodimerizing system comprises two components for the homodimerization, wherein the antigen binding domain comprising SEQ ID NO:1 (AB0) is the first component and a small molecule such as caffeine is the second component of the homodimerization, and wherein said AB0 and said small molecule form a complex of AB0/AB0/small molecule. Heterodimerizing systems obtained by said method are also disclosed herein.